Adults who took REYVOW™ (lasmiditan) C-V for their migraine attacks at doses of 100 mg or 200 mg had 3.8 and 4.6 times greater odds, respectively, of achieving pain freedom at 2 hours compared to those taking placebo (co-primary endpoint) ...
French biotechnology company Neovacs has signed an exclusive licence agreement with Centurion Pharma for IFNalpha Kinoid to treat patients with lupus in Turkey.